Rigel Pharma (RIGL) Announced Second FIT Phase 3 of Fostamatinib Did Not Meet Primary Endpoint
Tweet Send to a Friend
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced results for the second of two double-blind studies in the FIT Phase 3 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
